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Introduction
Amyotrophic lateral sclerosis (ALS) is a devastating neurodegenerative disease of the motor neuron system, for which no effective disease-modifying treatment exists. The disease is characterized by a significant variability in progression rates (1, 2) that imposes a challenge on patient stratification. Reliable biomarkers of disease progression would be valuable for ALS patient stratification prior to enrolment in clinical trials. Ideal biomarkers should remain stable during the course of disease and also be accessible, as in peripheral blood. To date, intensive research has identified only few peripheral blood ALS biomarkers (3-5), including cell-free neurofilaments (6) (7) (8) , and pro-inflammatory cytokines (9-11). microRNAs (miRNAs) are endogenous non-coding RNAs that are essential for motor neuron survival and are globally downregulated in post mortem ALS motor neurons (12) (13) (14) . While circulating miRNA profiles have been previously characterized in ALS (15) (16) (17) , the potential of miRNA biomarkers for ALS prognosis, and as readouts of disease progression has not yet been investigated. Here, we take an unbiased next generation sequencing (NGS) approach to comprehensively study plasma miRNAs in a large cohort of ALS cases and controls. We identified one miRNA, miR-181-5p, that is stable over time in individual patients. miR-181a-5p levels predict disease progression in an initial and second, validation cohort, demonstrating its use as a novel ALS biomarker.
Results
We used unbiased next generation sequencing to investigate, without an a priori bias, the 2 comprehensive landscape of plasma miRNAs in ALS patients and controls, for whom in depth clinical information was available (Table 1) . 4 First, we analyzed the differences between 115 ALS cases and 103 controls. Samples were prepared from total plasma RNA, as previously described (18), and profiled by small RNA 6 next generation sequencing (RNA-seq). Linear miRNA quantification was achieved via unique 12-nucleotide molecular identifiers (UMIs). 98% of samples cleared our threshold of 50,000 total 8 miRNA UMIs and were therefore included. miRNAs that were detected at ≥ 100 UMIs, on average across the 218 samples, were considered above noise level (a whole-cohort cut-off of We report 39 (/63) decreased (/increased) miRNAs in ALS samples relative to controls with adjusted p-values <0.05, Wald test, Figure S1A ). However, none of the 102 miRNAs that 1 6 were differentially expressed displayed satisfying diagnostic power. Specifically, three muscleenriched miRNA were elevated in ALS plasma: miR-206 (2.2 fold, adjusted p=6.6x10 -6 , Figure   1 8 S1B), miR-133a-3p and miR-133b (~1.5 fold, adjusted p=0.01). The area under the curve (AUC) for receiver-operating characteristic (ROC) curve of miR-206 differential expression showed a 2 0 modest predictive power for ALS diagnosis (AUC = 0.69, p<0.0001; Figure S1C ), in accordance with previous studies (19) (20) (21) . Beyond muscle-related miRNAs, miR-3168 was increased in ALS 2 2 vs controls (2.3 fold increase; adjusted p=6.6x10 -6 ).
To experimentally assess miRNA measurement variability (noise), we analyzed a 2 4 longitudinal sample cohort of 22 patients, for which blood samples were collected at four subsequent longitudinal time-points: t 1 -t 4 during the course of 30 months (2.5 years). Measured 2 6 variability between 22 individuals was low for 131/187 miRNAs (-log2 of t 4 /t 1 standard error >-0.2), and these were considered stable, while 56/187 other miRNAs exhibited higher variability 2 8 between patients and were excluded from further analysis ( Figure 1A , y-axis). For example, miR-181a-5p levels exhibited reduced variability at each time point across individual patients, four miRNAs (miR-423/484/92a/b) exhibited a robust increase in abundance from t 1 to t 4 ( Figure   1A , x-axis; Z-score of log2 t 4 /t 1 > 1.5 SD). miR-423/484/92a/b modestly increased early on 3 4 (~1.15 fold t 2 or t 3 relative to t 1 ), and further increased ~1.7-fold upon the fourth sampling (t 4 / t 1 , Figure S2A -C). The correlation of miR-423/484/92a/b levels to disease progression was longitudinal cohort (N=22-24 patients, one-tailed t-test: miR-484, p=0.01; miR-92a-3p, p=0.006; miR-92b-3p, p=0.04; Figure S3K -M), whereas miR-423-5p did not replicate the upward trend in 4 0 the second longitudinal cohort (one-tailed p-value=0.16, Figure S3J ).
The relative D50 (rD50), is a derivative of ALSFRS-R, that reveals the disease covered samplings from the same patients correlated with rD50 at the time of sampling ( Figure S4 ) and may be considered as candidate molecular biomarkers of the individual disease covered and thus 4 6 of ALS progression.
We next explored potential blood-borne miRNAs for prognosis biomarkers. An ideal 4 8 prognosis biomarker should be preferentially stable during the course of disease. We identified 127 miRNA candidate biomarkers, whose plasma levels were relatively stable during disease 5 0 progression ( Figure 1A ). We then correlated miRNA expression at enrolment to survival duration, calculated as lifespan from either symptom onset or from first phlebotomy at study 5 2 enrolment (on average 30.0±6 months after symptom onset). The levels of one miRNA, miR-181a-5p exhibited significant correlation to survival length (Spearman correlation coefficient -5 4 0.21, p=0.02, Figure 2A , S5A). Because miR-181a-5p levels remain stable in time ( Figure   1A ,B), it is unlikely that measurements are confounded by sampling at different disease stages.
6
The stability of miR-181a-5p during disease progression is also indirectly implied by comparable miR-181a-5p levels between patients sampled at different (early, progressive and late) disease Figure   S6A ) and by lack of correlation between miR-181a-5p levels and rD50 at enrolment ( Fig. S6B ).
0
We further subdivided patients in quartiles by the expression level of individual miRNA genes, and investigated how the low quartile (30 patients) compared to the rest of the cases (85 6 2 patients). Differences in plasma miR-181a-5p levels were able to predict survival length better than any other miRNA. Kaplan Meier curves revealed clear separation of survival between the 6 4 subgroups, based on plasma miR-181a-5p levels at enrolment (log-rank test chi-square=8.6, p=0.003, Figure 2B ). The median patient survival in the lower miR-181a-5p quartile was 36 6 6 months, compared to 13 months at the higher three quartiles. Thus, plasma miR-181a levels predict a substantial median survival difference of 23 months that is equivalent to a 280% 6 8 increase in survival length for patients with lower plasma miR-181a-5p levels. Comparable results were gained, when plasma miR-181a-5p levels at enrolment were stratified against 7 0 survival from reported first symptoms (disease onset, log-rank chi-square=9.4, p=0.002, Figure   2C ).
2
Noteworthy, patient individual disease covered at enrolment (rD50) was comparable between the low quartile of miR-181a-5p and the rest of the cases ( Figure S6C ). Furthermore, 7 4 enrolment progression rate, enrolment ALSFRS-R scores, and chronological age at onset were not correlated with miR-181a-5p levels, and these phenotypic features did not differ between the 7 6 low and high miR-181a-5p quantiles, except for a significant but modest increase in enrolment progression rate ( Figure S7A -F). These findings rule out the possibility that survival differences 7 8 between miR-181a-5p expression bins result from factors other than miR-181a-5p expression levels, such as the clinical status of the patients when they are sampled.
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The monthly mortality hazard ratio (HR) was calculated for different plasma miR-181a-5p quantiles and clinical covariates, by multivariate Cox regression analysis. This analysis allows 8 2 to calculate an independent hazard ratio for each covariate while holding the other covariates constant. High miR-181a-5p levels (top three quartiles) exhibited a hazard ratio of 2.35 (95% CI 8 4 1.4-3.9), relative to the lowest quartile when calculated from enrolment (Wald test p<0.001, Figure 3A ), and a hazard ratio of 2.4 when calculated from disease onset (95% CI, 1.5-4.0, 8 6 p<0.01, Figure 3B ). Enrolment progression rate, i.e. the rate of change in ALSFRS from symptom onset to enrolment, was also associated with a high hazard ratio of 2.16 for survival time from enrolment (95% CI 1.6-2.9, p<0.001, Figure 3A ), as previously reported (23). Taken together, higher enrolment miR-181a plasma levels associate with a considerably poor prognosis 9 0 in ALS, an effect which is not confounded by other phenotypic properties.
In order to validate our findings, we performed a replication study by measuring miR-9 2 181a-5p levels in plasma of an independent cohort of 56 patients (Table 1) by an orthogonal qPCR methodology. The replication study confirmed the existence of a prognostic gap of 180%, 9 4 from 14 to 25 months, between patients with high or low plasma miR-181a-5p levels, respectively (Log rank test: chi square=3.45, one-tailed p-value=0.03, Figure 4A ). The survival 9 6 difference was reproduced in the replication cohort, even when calculated from first reported symptoms (230%, 31 months from disease onset to 71 months, chi square=3.0, one-tailed p-9 8 value=0.04, Figure 4B ). Importantly, the average miR-181a-5p levels varied by 8-fold between the plasma of patients with better prognosis, relative to those with poor prognosis ( Figure 4C ), 1 0 0 suggesting a good dynamic range for biomarker quantification. Our data from two different cohorts of ALS patients establish miR-181a-5p as a new cell-free prognostic biomarker for ALS. In summary, we report the results of the most elaborated small RNA-seq study in ALS undertaken to date. Our work confirms the increase in muscle-enriched miR-206/133, which 1 0 4 plausibly reflects myotube content discharge from the muscular atrophy in ALS. We further show that miRNAs appear to mostly be unchanged longitudinally during disease, with the 1 0 6 exception of miR-423/484/92a/b, that increase over 30 months of disease. This feature could be used to monitor disease progression / individual disease covered and warrants further exploration 1 0 8
as pharmacodynamic biomarkers of response to therapy. Crucially, we find that miR-181a-5p levels predict shortened survival in two separate ALS cohorts. Intriguingly, the median survival
Materials and Method
Standard protocol approvals, registrations, and patient consents 1 1 8
All participants provided written consent (or gave verbal permission for a carer to sign on their behalf) to be enrolled in the ALS biomarkers study and ethical approval was obtained from the 1 2 0
East London and the City Research Ethics Committee 1 (09/H0703/27). 
Study design
Based on power analysis, we found that about 100 control and 100 ALS samples are required to survivors, , with the same power and p-value. We determined the sample size based on these calculations. Because sample processing was done in different batches, samples were randomly 1 2 8 allocated to the batches and within each batch, the number of control and ALS samples was balanced in order to reduce batch-associated bias. This study included a first cohort with 115 patients with ALS and 103 healthy controls from the ALS biomarker study. ALS patients were diagnosed according to standard criteria by Total RNA was extracted from plasma using the miRNeasy micro kit (Qiagen, Hilden, Germany) and quantified with Qubit fluorometer using RNA broad range (BR) assay kit (Thermo Fisher 1 5 0 Scientific, Waltham, MA). For small RNA next generation sequencing (NGS), libraries were prepared from 7.5 ng of total RNA using the QIAseq™ miRNA Library Kit and QIAseq miRNA 1 5 2 NGS 48 Index IL (Qiagen), by an experimenter who was blinded to the identity of samples. sequence, as defined by miRBase (28), were mapped using Geneglobe (Qiagen). StepOnePlus machine (Applied Biosystems). TaqMan qPCR was performed using Advanced MicroRNA Assays (reaction volume 10 μ L) with the following probes: hsa-miR-181a-5p 1 7 2 (Assay ID: 477857_mir); hsa-miR-423-5p (Assay ID: 478090_mir); hsa-miR-484 (Assay ID: 478308_mir); hsa-miR-92a-3p (Assay ID: 477827_mir); hsa-miR-92b-3p (Assay ID: Thus, the whole-cohort UMI cut-off was 100 ×218 = 21,800 UMIs). miRNA NGS data was 1 9 0 analyzed via DESeq2 package in R Project for Statistical Computing (30, 31) , under the assumption that miRNA counts followed negative binomial distribution and data were corrected excluded from analysis. Graphs were generated with GraphPad Prism 5. high quantiles.
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